PMS-Irbesartan/HCTZ Product Recall (2021-05-25)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
PMS-Irbesartan/HCTZ 300 mg/12.5 mg Tablet
| Lot or serial number | Brand name | Companies | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| 624235 | B. PMS-Irbesartan/HCTZ 300 mg/25 mg Tablet | - Recalling Firm
- Pharmascience Inc.
- 100, 6111 Royalmount Avenue
- Montreal
- H4P 2T4
- Quebec
- CANADA
- Marketing Authorization Holder
- Pharmascience Inc.
- 100, 6111 Royalmount Avenue
- Montreal
- H4P 2T4
- Quebec
- CANADA
| DIN 02328534 | Tablet | Irbesartan 300 mg |
| 621822, 621823, 625902, 625318, 629920, 631052, 632583 | PMS-Irbesartan/HCTZ 300 mg/12.5 mg Tablet | - Recalling Firm
- Pharmascience Inc.
- 100, 6111 Royalmount Avenue
- Montreal
- H4P 2T4
- Quebec
- CANADA
- Marketing Authorization Holder
- Pharmascience Inc.
- 100, 6111 Royalmount Avenue
- Montreal
- H4P 2T4
- Quebec
- CANADA
| DIN 02328526 | Tablet | Irbesartan 300 mg |
-
PMS-Irbesartan/HCTZ 300 mg/12.5 mg Tablet
-
PMS-Irbesartan/HCTZ 300 mg/25 mg Tablet
Presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in affected lots.